Follow-up and Treatment Workgroup Report:

The Role of Quality Measures to Promote Long-Term Follow-up of Children Identified by Newborn Screening Programs

ACHDNC Meeting, February 8, 2018
Jeffrey P. Brosco MD PhD
Committee Member
Chair, Follow-up and Treatment Workgroup
Acknowledgements: Authors, Reviewers, and Staff

AUTHORS

• Alan E. Zuckerman*, Georgetown University (Lead Author)
• Deborah Badawi, University of Maryland School of Medicine
• Jeffrey P. Brosco, University of Miami (Workgroup Chair)
• Amy Brower*, American College of Medical Genetics and Genomics
• John Eichwald, Centers for Disease Control and Prevention
• Lisa Feuchtbaum, California Department of Public Health
• Terese Finitzo, OZ Systems
• David Flannery, American College of Medical Genetics and Genomics
• Nancy Green, Columbia University
• Carol Greene, Society for Inborn Errors of Metabolism Disorders
• Kathryn Hassell*, University of Colorado Denver
• Nancy Doan Leslie, Cincinnati Children’s Hospital Medical Center
• Sylvia Mann, Hawaii State Department of Health
• Kamila B. Mistry, AHRQ/OEREPE
• Jana Monaco*, Organic Acidemia Organization
• Margie A. Ream, Nationwide Children’s Hospital
• Joseph Schneider, University of Texas Southwestern
• Stanley Sciortino, California Department of Public Health
• Rani Singh, Emory University
• Marci Sontag, University of Colorado Denver
• Janet Thomas, Children’s Hospital Colorado
*Quality Measures Sub-Workgroup Co-Chair

REVIEWERS

• Sue A. Berry, University of Minnesota
• Christine S. Brown, National PKU Alliance
• Kathryn Camp, Nutritionist
• Rebecca Goodwin, NIH/NLM/LHC
• Debra Freedenberg, Texas Department of State Health Services
• Celia Kaye, University of Colorado Denver
• Christopher Kus, Assoc. of State and Territorial Health Officials (Workgroup Co-Chair)
• Stephen McDonough, University of North Dakota (former Workgroup Chair)
• Robert J. Ostrander, SUNY Upstate Medical University
• Annamarie Saarinen, Newborn Foundation

HRSA STAFF

• Mia Morrison
• Catharine Riley
• Joan Scott
• Jill Shuger
The Report

• Drafted in response to the February 2016 Charge to the Workgroup:
  • Promoting the role of clinical quality measures to promote long-term follow-up

• Aim:
  • Focus on the use of quality measures to assess and help drive long-term follow-up in NBS
    • Describe quality measures
    • Provide case studies as examples of what is currently being done in the field of NBS and related fields
    • Identify gaps and possible next steps

• Dissemination Plan:
  • If there is consensus from the Committee, post the report on the Committee’s website
    • Encourage NewSTEPs, NBSTRN, NCC, Genetic Alliance, etc. to highlight report
  • Pursue publication of the executive summary
  • Encourage colleagues in specialty areas of medicine and public health that intersect with newborn screening to build on the information provided in the report to develop manuscripts relevant to their specialty (e.g. pediatric neurologists)
Possible Next Steps Identified in the Report

• Engage a broad range of stakeholders (e.g. Federal, State, Provider, and Consumer groups, Professional Organizations) to:
  • participate in LTFU of NBS.
  • leverage research networks that collect data from patients and families to participate in quality measure development and quality improvement activities targeted to LTFU of NBS.

• Identify a core set of long term follow-up quality measures and associated data resources for conditions identified by newborn screening.

• Encourage the use of large data collection activities such as the National Survey of Children’s Health (NSCH) and quality improvement activities such as Medicaid quality reporting and HEDIS to provide data on LTFU of NBS.

• Assist the use of new Health Information Technology (HIT) standards for implementing and sharing quality measures as a strategy for integrating quality measures into routine care and using Clinical Decision Support (CDS) in the EHR to capture data and guide care.
Questions?

Committee Discussion